Simcere's ENWEIDA® Phase III Neoadjuvant/Adjuvant Trial in Resectable NSCLC Completes Full Patient Enrollment
May 22, 2026 13:50
CST Updated
14:13
Simcere
Innovative Drug Developer
3D Medicines
Developer of Tumor Immunotherapy Drugs
Simcere Zaiming
Developer of Innovative Anti-Tumor Drugs